A Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation
← catalyst calendarNCT04002297 · readout ≤ 224 d
Sponsored by BeOne Medicines (industry) · ONC — their whole pipeline →.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
510actual
Sites
176
Countries
Australia, Austria, Belgium +19
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2019-08-20 | actual | When the study began enrolling |
| Primary completion | Mar 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2031-09-30 | estimated | The whole study's end, after follow-up |
| First posted | 2019-06-28 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-18 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Mantle Cell Lymphoma; Non-Hodgkin Lymphoma
Interventions
- Drug: zanubrutinib — also filed as BGB-3111, Brukinsa
- Drug: bendamustine
- Drug: rituximab
Primary outcome
what the primary-completion date above is the date OFProgression-free survival (PFS) determined by independent central review
measured Up to approximately 7 years
Publications
- PMID 32985902 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · ONC's whole pipeline · Catalyst calendar · Every registered study · What changed